-
Tokyo, Munich and Basking Ridge, NJ – February 22, 2021 – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced Ken Takeshita, MD will be named the new Global Head of Research & Development as of April 1, 2021. On that date, Dr. Junichi Koga will retire from the position,…
Daiichi Sankyo2021-02-22 13:14:52Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D -
Ken Keller Appointed as Head of the Oncology Business Unit Overseeing Global Oncology Strategy and U.S. and European Oncology Businesses
Daiichi Sankyo2020-11-11 20:09:14Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organization -
• Agreement represents second collaboration between Daiichi Sankyo and AstraZeneca for a Daiichi Sankyo DXd antibody drug conjugate (ADC) • AstraZeneca to pay Daiichi Sankyo up to $6 billion in total consideration, including a $1 billion upfront payment and up to an additional $5 billion contingent…
Daiichi Sankyo2020-08-03 09:16:13Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi -
Tokyo, Japan, Munich, Germany, Basking Ridge, NJ (November 4 / 5, 2019): Daiichi Sankyo Co., Ltd announced today that the company has filed a Declaratory Judgement action in the District Court of Delaware in response to receiving communications from Seattle Genetics, Inc. with respect to a…
Daiichi Sankyo2019-12-12 16:00:02Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugate -
• Collaboration combines Daiichi Sankyo’s scientific and technological excellence with AstraZeneca’s global experience and resources in oncology to accelerate and expand the potential of [fam-] trastuzumab deruxtecan as monotherapy and combination therapy across a spectrum of HER2 expressing cancers…
Daiichi Sankyo2019-05-28 13:30:01Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi -
- Dr. Junichi Koga to become new global Head of Research & Development Unit and Co-Chair of the company's Global Executive Meeting of R&D (GEMRAD), the top decision-making body in R&D - Ken Keller appointed President & CEO of Daiichi Sankyo, Inc., a U.S. affiliate - Dr. Glenn Gormley successfully…
Daiichi Sankyo2019-05-28 13:30:01Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase -
New video-based website on cancer answers most frequently asked patient questions and simplifies medical jargon in 16 (EU & minority) different languages.
Daiichi Sankyo2018-11-22 13:00:01Daiichi Sankyo Europe launches mycancertherapy.eu at ESMO 2018 -
Intended for US and EU Medical Media Only - Significant investment in antibody drug conjugate (ADC) manufacturing capabilities will improve research productivity and accelerate clinical development of novel Daiichi Sankyo Cancer Enterprise ADC candidates including HER2-targeting DS-8201and…
Daiichi Sankyo2017-08-14 17:45:01Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug